- Home
- IGMS vs IMAB Comparison
IGMS vs IMAB Comparison
Compare IGMS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- IMAB
- Stock Information
- Founded
- IGMS 1993
- IMAB 2014
- Country
- IGMS United States
- IMAB United States
- Employees
- IGMS N/A
- IMAB N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- IGMS Health Care
- IMAB Health Care
- Exchange
- IGMS Nasdaq
- IMAB Nasdaq
- Market Cap
- IGMS 82.1M
- IMAB 79.9M
- IPO Year
- IGMS 2019
- IMAB 2020
- Fundamental
- Price
- IGMS $1.38
- IMAB $0.97
- Analyst Decision
- IGMS Hold
- IMAB Strong Buy
- Analyst Count
- IGMS 8
- IMAB 3
- Target Price
- IGMS $6.14
- IMAB $8.00
- AVG Volume (30 Days)
- IGMS 368.0K
- IMAB 270.1K
- Earning Date
- IGMS 03-06-2025
- IMAB 03-13-2025
- Dividend Yield
- IGMS N/A
- IMAB N/A
- EPS Growth
- IGMS N/A
- IMAB N/A
- EPS
- IGMS N/A
- IMAB N/A
- Revenue
- IGMS $2,918,000.00
- IMAB $569,464.00
- Revenue This Year
- IGMS $26.85
- IMAB N/A
- Revenue Next Year
- IGMS $125.17
- IMAB N/A
- P/E Ratio
- IGMS N/A
- IMAB N/A
- Revenue Growth
- IGMS 57.64
- IMAB N/A
- 52 Week Low
- IGMS $1.26
- IMAB $0.84
- 52 Week High
- IGMS $22.50
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- IGMS 26.21
- IMAB 46.51
- Support Level
- IGMS $1.26
- IMAB $0.96
- Resistance Level
- IGMS $1.54
- IMAB $1.04
- Average True Range (ATR)
- IGMS 0.13
- IMAB 0.05
- MACD
- IGMS 0.22
- IMAB -0.00
- Stochastic Oscillator
- IGMS 29.27
- IMAB 36.36
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).